


CLINICAL CONSIDERATIONS FOR ADVANCED HEART FAILURE SOLUTIONS*



*Assessment indicators are exemplars only based on the referenced literature. Clinicians are responsible for making independent, patient-specific, clinical determinations regarding the medical necessity of any advanced interventions and for ensuring that all medical decisions are in the clinical best interest of the patient.

**Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head to head comparison. Data presented for informational purposes only.

***Compared to the HeartMate II™ LVAD in the MOMENTUM 3 trial.

1. Kirklin J, Naftel D, Pagani F, et al. Seventh INTERMACS annual report: 15,000 patients and counting. *J Heart Lung Transplant.* 2015;34(12):1495-1504.
 2. Saeed M, Hanna I, Robotis D, et al. Programming ICD in patients with primary prevention indication to prolong time to first shock PROVIDE study. *J Cardiovasc Electrophysiol.* 2014.
 3. Epstein, A. Benefits of the implantable cardioverter-defibrillator. *J Am Coll Card.* 2008.

4. Abraham W, Fisher W, Smith A, et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med.* 2002;346(24):1845-1853.
 5. Stone G, Lindenfeld W, Abraham S, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med.* 2018;379:2307-18.
 6. Abraham W, Adamson P, Bourge R, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. *The Lancet.* 2011;377(9766):658-66.
 7. Shavell D, Desai A, Abraham W, et al. Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure Patients in Clinical Practice: 1-Year Outcomes from the CardioMEMS Post Approval Study. Presented at ACC; March 17, 2019.
 8. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist Device-Final Report. *N Engl J Med.* 2019; 380:1618-1627.
 9. Khush K, Cherikh W, Chambers D, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report—2018; Focus Theme: Multiorgan Transplantation. *J Heart Lung Transplant.* 2018;37(10):1155-1168.

10. Aziz T, Singh G, Popjes E, Stephenson, E., et al. Initial experience with CentriMag extracorporeal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock. *J Heart Lung Transplant.* 2010;29(1):66-71.
 11. Bhama J, Kormos R, Toyoda Y, et al. Clinical experience using the Levitronix® CentriMag system for temporary right ventricular mechanical circulatory support. *J Heart Lung Transplant.* 2009;8(9):971-976.
 12. John R, Long J, Massey H, et al. Outcomes of a multicenter trial of the Levitronix® CentriMag ventricular assist system for short-term circulatory support. *J Thorac Cardiovasc Surg.* 2011;141(4):932-939.
 13. Daubert J, Saxon L, Adamson P, et al. EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. *Euro Soc Card.* 2012;14:1236-1286.
 14. Mullens W, Grimm R, Verga T, et al. Insights from a cardiac clinic as part of a heart failure disease management program. *JACC.* 2009;53(9):765-773.
 15. Curtis A, Worley S, Adamson P, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. *N Engl J Med.* 2013;368:1585-93.

16. Stone G, Lindenfeld W, Abraham S, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med.* 2018;379:2307-18. As presented at ACC Annual Meeting, New Orleans, LA, March 17, 2019.
 17. Fang J, Ewald G, Allen L, et al. Advanced (Stage D) Heart Failure: A statement from the HFSA guidelines committee. *J Card Fail.* 2015;21(6):519-534.

Abbott
 The Corporate Village, Da Vincilaan 11 Box F1, 1935 Zaventem, Belgium
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
 ™ Indicates a trademark of the Abbott group of companies.
 ‡ Indicates a third party trademark, which is property of its respective owner.
 © 2019 Abbott. All Rights Reserved.
 SJM-HGEN-0518-0054(4)d Information contained herein intended for audiences from outside the United States only.

